INTRODUCTION
Vitelliform macular dystrophy (Best's disease; VMD2; OMIM 153700) is a progressive autosomal dominant disorder with juvenile onset that causes loss of visual acuity by the sixth or seventh decade due to atrophic macular changes or choroidal neovascularization associated with subretinal haemorrhages and fibrosis (1) . In the early stages, the disease is characterized by abnormal depositions of lipofuscin-like material at the level of the retinal pigment epithelium (RPE) classically resembling an egg yolk (Fig. 1) . Later, disintegration of the central yellow lesions progressively leads to vision loss. Although the biochemical abnormalities in Best's disease are unknown, both histopathology of diseased eyes (2) and a typical reduced light rise of the ocular potential in the electrooculogram (EOG) (3) suggest that the defect arises in the RPE.
In 1992, following the initial steps of the positional cloning strategy, genetic linkage analysis mapped the Best's disease gene, designated VMD2, to 11q13 (4, 5) . Subsequently, further studies refined the chromosomal location of the gene (6) (7) (8) (9) (10) and finally narrowed the VMD2 locus to a 980 kb interval flanked by polymorphic DNA loci D11S4076 and uteroglobin (UGB) (11, 12) . The critical Best's disease region was isolated in overlapping YAC (13) and sequence-ready PAC clones (14) . This has facilitated the partial characterization of a number of novel transcripts within the interval by using various gene identification approaches including exon trapping, direct cDNA selection, expressed sequence tag (EST) mapping and computer-based analyses of genomic sequences (15, 16) .
In order to identify the VMD2 gene causing Best's disease, we fully characterized a total of nine novel genes located within the critical region (16; A. Marquardt et al., in preparation). We have determined their expression profiles as well as their genomic organizations, and subsequently have analysed their exonic sequences for the presence of mutations in patients from multigeneration Best's disease pedigrees. By northern blot analysis, one of the genes, termed TU15B, was found to be expressed exclusively in RPE as a single 2.4 kb transcript. Mutational analysis of TU15B identified heterozygous sequence changes in 12 patients analysed but not in control individuals. For 10 sequence changes, segregation with the disease was shown in multigeneration families. Our data provide strong evidence that mutations in TU15B are associated with Best's disease and that this gene represents the VMD2 gene. Although database analysis of the putative translation product of TU15B reveals a high degree of sequence conservation throughout evolution, nothing is known about the functional properties of this novel gene.
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RESULTS

Identification and genomic organization of TU15B
Computer-based analysis of partial genomic sequences from the PAC clones dJ519O13, dJ466A11 and dJ756B9 facilitated the identification of several overlapping EST clones. Two of these clones originated from retinal (EST20422, EST19416), one from melanocyte (yx55d08) and one from neuron-derived (zq47a06) cDNA libraries (Fig. 2) . Alignment of EST clones EST20422, EST19416 and yx55d08 to the genomic sequences revealed several splicing events in the cDNAs delineating four exons corresponding to exons 8-11 of a novel transcript, designated TU15B (Fig. 2, Table 1 ). Coding prediction utilizing ∼20 kb of sequence upstream of exon 8 identified another six exons (exons 2-7). The acceptor and donor splice consensus sequences were in the same orientation as determined for exons [8] [9] [10] [11] . To verify the predicted exons, RT-PCR using oligonucleotide primers forward F4 (designed within exon 2) and reverse R2 (designed within exon 9) was performed with RPE mRNA. The resulting 975 bp cDNA fragment was sequenced directly and aligned to the genomic sequence, confirming predicted exons 2-7. Finally, alignment of the cerebellum-derived EST29952 sequence identified an additional exon (exon 1) 1.3 kb upstream of exon 2 ( Fig.  2 , Table 1 ). Figure 2 . The Best's disease candidate region between D11S4076 and UGB (11, 12) and relative position of the VMD2 gene centromeric to FTH1 based on genomic sequence analysis of PAC clones dJ519O13, dJ466A11 and dJ756B9. The genomic organization of the exon/intron structure of VMD2 is given in relative spacing. The orientation of transcription of the VMD2 gene is indicated by an arrow. The 5′-and 3′-untranslated regions are represented by hatched boxes. Overlapping EST and RT-PCR clones used to characterize the genomic structure of VMD2 are shown. Alternative splicing of clone zq47a06 is indicated. Assembly of overlapping EST and RT-PCR fragments corresponding to exons 1-11 results in a cDNA fragment of 2192 bp. A putative poly(A) signal, AAUAAA, is predicted at nucleotide positions +2166 to +2171. The cDNA contains an open reading frame (ORF) of 1843 bp with a first potential in-frame translation initiation codon, ATG, starting 89 nucleotides downstream.
Based on the genomic sequence, an in-frame stop codon is present 243 bp upstream of the potential translation initiation start site. Therefore, the mature protein predicted from the ORF consists of 585 amino acid residues, resulting in a calculated molecular mass of 67.7 kDa and an isoelectric point of 6.5. Several potential N-linked glycosylation sites are predicted at amino acid positions 190-193 (NLSM), 365-368 (NISL) and 540-543 (NLTD) (Fig.  3) . Five cysteine residues are present in the protein and may participate in intra-and/or interchain disulfide bonding.
Alignment of Est clone zq47a06 to the genomic sequence indicates an alternative splicing event that causes skipping of exons 7-9 and consequently splicing of exons 6 and 10 ( Fig. 2) . If confirmed by further cDNA cloning, the shortened transcript is predicted to consist of 270 amino acid residues with a calculated molecular mass of 31.5 kDa and an isoelectric point of 9.8.
Homology to the RFP protein family
Protein database analysis of the predicted amino acid sequence of TU15B revealed significant homologies to the RFP protein family that include proteins identified in several nematode species, the fruit fly Drosophila melanogaster and the mouse (Fig. 4) . The members of this family share a conserved sequence of ∼350-400 amino acid residues including an invariant RFP motif and a large number of highly conserved aromatic amino Northern blots with poly(A) + RNA from heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas and total RNA from lung, cerebellum, retina, RPE cell line ARPE-19 and RPE were hybridized with the 975 bp cDNA fragment F4R2 corresponding to exons 2-9 of VMD2. A distinct band of 2.4 kb in size is present exclusively in RPE tissue.
acid residues (F, W, Y) (Fig. 4) . Thus far, the RFP family is known only from genomic and EST sequences, and no functional properties have been assigned to any of the growing number of family members.
Expression analysis of TU15B
The expression profile of TU15B was investigated using a multiple tissue northern blot containing poly(A) + RNA from various adult human tissues, including heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas, and a second northern blot containing total RNA from lung, cerebellum, retina, RPE cell line ARPE-19 and RPE (Fig. 5) . The blots were hybridized with RT-PCR cDNA probe F4R2 representing coding exons 2-9. A single transcript of 2.4 kb was detected in RPE tissue, but not in any of the other tissues tested. Isolated EST clones representing parts of the TU15B transcript were identified from various tissues including cerebellum, retina, melanocyte, colon and breast tumour (Fig. 2) possibly indicating minor transcriptional activity or ectopic expression in these tissues.
Mutational analysis in Best's disease patients
DNA samples from affected and unaffected probands from 10 of the 12 Best's disease families were available for mutational analysis of TU15B. In families O and G, DNAs were available only from the respective index patients. Haplotyping of 10 families with markers at D11S1765, D11S4076 and UGB indicated that families N and W share a common disease allele for affected individuals. Distinct haplotypes were found for the remaining eight disease chromosomes (unpublished data).
Mutation screening of TU15B was performed by singlestranded conformational analysis (SSCA) using oligonucleotide primers flanking the 11 exons (Table 2) . Individual exons that demonstrated aberrant band shifts were sequenced directly. This led to the identification of 11 distinct sequence changes in the Best's disease patients including 10 missense mutations and a single amino acid deletion of an isoleucine at codon 295. The ∆I295 is shared by families N and W as predicted from the haplotyping results (Figs 3, and 6a and b; Table 3 ). The segregation of ∆I295 with the disease in the three-generation family N is shown in Figure 6a .
The 10 missense mutations were identified exclusively in coding exons 2, 6 and 8 and were V9M, A10T, W24C, R25Q, R218Q, Y227N, Y227C, V235M, P297A and F305S (Figs 3 and 6c-f; Table 3 ). Nine of these mutations occur at phylogenetically highly conserved amino acid residues (Fig. 3) . All mutations were shown to segregate with the disease (Fig. 6a and data not shown) with the exception of V9M and W24C, as no additional DNA samples from families O and G were available. A total of 84 control chromosomes analysed by SSCA in exons 2, 6 and 8 showed no mobility shifts resembling the known missense mutations (data not shown). Similarly, the ∆I295 mutation was not found in the 84 control chromosomes (data not shown). A total of seven frequent polymorphic sequence changes were found (Table 4) .
DISCUSSION
We report the identification and characterization of a novel gene, TU15B, that is located close to the ferritin heavy chain-1 (FTH1) gene within the critical region containing the Best's disease gene. Several lines of evidence suggest that TU15B is in fact the gene (designated VMD2) responsible for Best's disease. First, this gene is expressed exclusively in the RPE, the tissue that is thought to be the primary site of pathology in Best's disease, suggesting that the protein plays a functional role in the RPE (2, 17, 18) . Second, heterozygous sequence changes were identified in all affected individuals but not in control individuals and, wherever possible, we have confirmed that the mutational changes segregate in the respective families. Third, nine out of 10 missense mutations affect phylogenetically highly conserved amino acid residues and, therefore, would be predicted to influence protein function. In particular, mutations W24C, Y227N, Y227C and F305S change aromatic amino acid residues that are invariant among the members of the putative RFP family of proteins (Fig. 3) . Our data provide strong evidence that TU15B is indeed the VMD2 gene that is mutated in Best's disease.
At present, it is not clear whether the EST and RT-PCR assembly has yielded the full-length VMD2 transcript, particularly at the 5′ end of the cDNA. 5′-RACE experiments have not allowed us to expand the transcript further in this direction. Nevertheless, starting from the 5′ limit of the ORF, we have tentatively assigned the first in-frame ATG as the potential start codon for initiation of translation. Protein sequence alignment of the N-termini of the various members of the conserved RFP family is in agreement with a location of the start codon at this position (Fig. 4) . However, close inspection of the sequence context around the putative VMD2 start codon, CTGGCCATGA, suggests that this consensus motif should be rather weak, as the nucleotides in the two key positions (positions G -3 and A +4) do not conform to the postulated consensus, namely A -3 and G +4 (19) . Further cDNA cloning will be required to resolve this uncertainty. In addition to EST sequences representing the VMD2 transcript, database searches with six-frame translations of the VMD2 cDNA sequence versus six-frame dbEST identified several additional EST clones having significant sequence identities to the VMD2 protein (Fig. 4) . These partially overlapping EST sequences (e.g. zf24a04, af06b11, zj85b06, nk99g10, ot81f12) are derived from various human tissues including fetal heart, testis, fetal liver/ spleen, tumour and total fetus, indicating different temporal and spatial tissue distribution compared with VMD2. By EST mapping to overlapping PAC clones, we have excluded additional VMD2-related sequences from the Best's disease region. In light of the fact that VMD2 is associated with Best's disease, it will be interesting to elucidate the possible role of other members of this highly conserved protein family in human disease.
Several authors have suggested that Best's disease shares some clinical features with age-related macular degeneration (AMD) (4, 6, 12) . Both disorders are characterized by an abnormal subretinal accumulation of lipofuscin-like material in the early stages of the disease. In addition, in both conditions, a subset of patients suffers loss of visual acuity from either subretinal neovascularization or extensive atrophic changes in the macular area. The identification of the Best's disease gene will allow us to determine whether this gene could be involved directly in a predisposition to the genetically complex AMD. This would not be without precedence as mutations in the retina-specific ABC transporter (ABCR) have been shown to be involved not only in monogenic retinal dystrophies such as the autosomal recessive Stargardt's disease (20) , retinitis pigmentosa (21, 22) and cone-rod dystrophy (21) , but also appear to confer susceptibility to the atrophic, dry form of AMD in a substantial number of patients (23) .
In conclusion, the results of our study provide strong evidence that TU15B is indeed the VMD2 gene and that, when mutated, it causes Best's disease. So far, we have found disease-associated mutations in all patients analysed, suggesting that Best's disease is a genetically homogenous condition. The vast majority of mutations represent missense mutations affecting positions in the protein that are highly conserved throughout evolution and, therefore, are thought to exert deleterious effects on normal protein function possibly through a dominant-negative effect. The identification of the VMD2 gene now facilitates the investigation of the precise molecular pathology underlying Best's disease. Besides RPE65 (24, 25) , VMD2 is the second RPE-specific gene associated with a human retinal dystrophy.
MATERIALS AND METHODS
Computer-based analysis of genomic sequences
The construction and assembly of overlapping PAC clones spanning the critical Best's disease region have been reported elsewhere (14) . Of these, genomic sequences from PAC clones dJ519O13, dJ466A11 and dJ756B9 (Fig. 2) are currently generated by the Genome Science and Technology Center (GESTEC) at the Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, and are available at the Web site http://gestec.swmed.edu/ . The sequences were used to search the public dbEST database at http://www2.ncbi.nlm.nih.gov/dbEST/ index.html . The BLAST program of the GCG Wisconsin package was used to search for similarities with known DNA or protein sequences (26) . The genomic sequences were assessed for coding potential using XGRAIL1.3 (27) at http://dot. imgen.bcm.tmc.edu:9331/seq-search/gene-search.html , and the FGENE Web tool available at http://genomic.sanger.ac.uk/ gf/gf.html .
cDNA cloning and genomic organization
The cDNA of TU15B was assembled from overlapping EST clones and from RT-PCR fragment F4R2 connecting GRAIL2-predicted exons 2 and 9 (Fig. 2) . For RT-PCR, reverse-transcribed total RNA from human RPE and exonic oligonucleotide primers TU15B-F4 (5′-CAT GAC CAT CAC TTA CAC AAG C-3′) and TU15B-R2 (5′-ATC TCA TCC ACA GCC AAC AG-3′) were used. Direct DNA sequencing was performed using the Thermo Sequenase radiolabelled terminator cycle sequencing kit (Amersham). Alignments of cDNA and genomic sequences from PAC clone dJ466A11 were performed using MacVector Version 4.1.4 (Kodak, New Haven, CT), allowing the assignment of donor and acceptor splice recognition sequences (Table 1) .
Northern blot hybridizations
Total RNA was isolated using the guanidinium thiocyanate method (28) . Each lane contains 12 µg of total RNA from lung, cerebellum, retina, RPE cell line ARPE-19 (kindly provided by Dr L.M. Hjelmeland, University of California, Davis, CA) and RPE tissue and was electrophoretically separated in the presence of formaldehyde. A multiple tissue northern (MTN) blot was purchased from Clontech Laboratories (Palo Alto, CA). It was prepared from poly(A) + RNA isolated from human heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. The 975 bp F4R2 fragment was used for filter hybridization at 65_C in 0.5 mM sodium phosphate buffer, pH 7.2; 7% SDS, 1 mM EDTA at 65_C (29) . To test for equal loading and the integrity of the RNA, the northern blots subsequently were hybridized with a human β-actin cDNA probe provided with the MTN blot.
Patients and mutational analysis
A detailed clinical description of the multigeneration Best's disease families D, Di, H, N, R and W has been published elsewhere (7, 8, 30, 31) . Affected members in family C (five individuals), family F (eight individuals), family G (three individuals), family O (three individuals), family S (three individuals) and family T (five individuals) were diagnosed with Best's disease based on (i) a positive family history of multiple affected individuals in at least two generations; (ii) dilated fundus examinations revealing typical macular lesions in at least one affected member of the family; and (iii) subnormal light/dark ratios in the EOG.
Peripheral EDTA-blood samples were available from affected and unaffected members of the 12 Best's disease pedigrees.
Genomic DNAs were extracted using standard techniques. Genotyping was performed with markers at D11S1765, D11S4076 and UGB tightly flanking the Best's disease locus (11, 12) . Disease-associated haplotypes could be constructed in each case (31 and unpublished data). For SSCA, genomic DNAs were PCR amplified using oligonucleotide primers designed from intronic sequences ( Table 2) . Amplification of the coding exons was carried out with Taq polymerase (Gibco BRL) in a 25 µl volume in 1× PCR buffer supplied by the manufacturer. PCR products were electrophoretically separated on a 6% non-denaturing polyacrylamide gel with or without 10% glycerol at 4_C. DNA fragments revealing mobility shifts were sequenced directly using the PRISM Ready Reaction Sequencing Kit (Perkin Elmer-Cetus) and analysed on an ABI310 automated sequencer.
Computational protein analysis
Protein motif searches were carried out with ProDom database release 34.1 (http://protein.toulouse.inra.fr/prodom/prodom.html ) and the ProSite algorithms available at http://dot.imgen. bcm.tmc.edu:9331/seq-search/protein-search.html . Protein sequences were aligned using the multiple alignment program Pileup of the GCG Wisconsin package (26) and shaded using version 3.21 of BOXSHADE (http://ulrec3.unil.ch/software/ BOX_form.html ).
